11 research outputs found
Angiopoietin-1 promotes functional neovascularization that relieves ischemia by improving regional reperfusion in a swine chronic myocardial ischemia model
10.1007/s11373-006-9082-xJournal of Biomedical Science134579-59
Cellular myocardial reconstruction using human myoblasts [2]
10.1016/S0735-1097(03)00710-1Journal of the American College of Cardiology423589JACC
Myoblast transplantation for heart failure – From bench to bedside
Heart failure causes morbidity and mortality. Cell transplantation using skeletal muscle myoblast is promising for myocardial repair as it can regenerate and repair the injury. Skeletal myoblasts are unipotent progenitor cells that can be expanded and genetically modified to deliver angiogenic cytokines and growth factors to encourage angiomyogenesis. Myoblast transplantation inhibits ventricular remodelling, decreases left ventricular diastolic dimension, increases myocardial wall thickness and minimizes global ventricular dilatation in animals. Ongoing trials with skeletal myoblast transplantation show improvement in perfusion and metabolic activity. Time constraints and the problem of generating autologous skeletal myoblasts for every patient can be overcome if allogeneic skeletal myoblasts from healthy young donors can be made available. Myoblast transplantation is confronted with the problem of donor cell survival post-transplantation. Its safety and feasibility have been documented during animal and phase I studies. The only serious postoperative adverse event related to the procedure was ventricular arrhythmias. The results of phase I studies are still preliminary. Endpoint measurements highlight improvement in quality of life, reduced nitroglycerine consumption, enhanced exercise tolerance, improvement in NYHA Class and wall motion by echocardiography, and significantly reduced perfusion defects. Future directions include concerted collaborative efforts, strict inclusion and exclusion criteria, better establishment of target population. Further work needs to be done on the ideal cell type, optimal number of cells and route of administration. The most suitable time for cell transplantation after ischemic injury and optimal mode of cell delivery are evaluated. The use of cell-based techniques to assist with cardiac regeneration holds promise for the treatment of heart failure
1116-2 Delivery of human myoblasts transduced with a novel bicistronic vector carrying human vascular endothelial growth factor165and angiopoietin-I forms mature blood vessel in the heart
Congenital ostial membrane of right coronary artery in complete transposition of the great arteries
Angiopoietin-1 for myocardial angiogenesis: A comparison between delivery strategies
10.1016/j.ejheart.2006.10.022European Journal of Heart Failure95458-465EJHF
Reversal of myocardial injury using genetically modulated human skeletal myoblasts in a rodent cryoinjured heart model
European Journal of Heart Failure76945-95